In this episode of MedTech Global Insights, we explore the complexities of medical device classification with Singapore's Health Sciences Authority (HSA). While Singapore is a key entry point into the Asian MedTech market, its regulatory system holds unique challenges that can lead to costly delays for foreign manufacturers. We break down the HSA's risk-based classification system and reveal how subtle interpretations of your product's "intended purpose" can dramatically alter your path to market. This episode is essential listening for any MedTech company planning an expansion into Asia. A prime example involves a US-based AI diagnostic software company. They targeted Singapore assuming a medium-risk Class C classification similar to their home market. However, the HSA's interpretation of their software's direct diagnostic claims pushed the product into the highest-risk Class D. This single change delayed their launch by over a year and required a new, unforeseen set of clinical data, illustrating a critical pain point we help you avoid. What you'll learn in this episode: - Why is Singapore's "highest risk class applies" rule a major trap for manufacturers? - How can the precise wording of your "intended purpose" dramatically change your registration pathway with the HSA? - What are the most common classification mistakes foreign MedTech companies make when entering Singapore? - For Software as a Medical Device (SaMD), what specific claims are most likely to trigger a high-risk classification from the HSA? - How does your existing FDA or CE marking approval impact your HSA submission, and where can things go wrong? - What key documentation must be flawless before you even attempt to classify your device for the Singaporean market? - How can expert regulatory consulting de-risk your entire Asia-Pacific expansion strategy, starting with a successful Singapore entry? For a consultation on your market access strategy, contact us at [email protected] or visit https://pureglobal.com/.